This study provided a new perspective for the treatment of CHD, that is, UBE2I accelerated the degradation of NLRP3 through the SUMOylation pathway, thereby exerting an anti-pyroptosis effect. Therefore, UBE2I was a promising therapeutic target for CHD.
Shengkai Ding (Fri,) studied this question.